A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis Clinical Trial

Official title:
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Status Completed

Clinical Trial Summary

This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00477672
Study type	Interventional
Source	ACADIA Pharmaceuticals Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	June 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06068465` - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Phase 3
Recruiting	`NCT04373317` - Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis	Phase 4
Completed	`NCT01518309` - An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients	Phase 2
Completed	`NCT00658567` - A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT01174004` - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT00550238` - A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Recruiting	`NCT05590637` - Comparing Antipsychotic Medications in LBD Over Time	Phase 4
Approved for marketing	`NCT02762591` - Expanded Access of Pimavanserin for Patients With PD Psychosis	N/A